PBYI Jul 2024 7.500 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 10:29AM EDT. Market open.
| Previous close | 0.1400 |
| Open | 0.0500 |
| Bid | 0.0000 |
| Ask | 0.0500 |
| Strike | 7.50 |
| Expiry date | 2024-07-19 |
| Day's range | 0.0500 - 0.0500 |
| Contract range | N/A |
| Volume | |
| Open interest | 41 |
Business WirePuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
LOS ANGELES, June 07, 2024--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on June 6, 2024, the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement restricted stock unit award covering 3,500 shares of Puma common stock to one new non-executive employee.
Business WirePuma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer
LOS ANGELES, June 03, 2024--Puma Biotechnology Announced Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer at the 2024 ASCO Annual Meeting.
Business WirePuma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)
LOS ANGELES, June 02, 2024--Puma Biotechnology announced that findings from the Phase II trial of its drug alisertib (TBCRC 041) were presented at the ASCO 2024 Annual Meeting.
© 2024 Yahoo. All rights reserved.